Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of plerixafor and bortezomib,
and the highest dose that can be given to people safely. Plerixafor appears to stop myeloma
cells from attaching to bone marrow and has been used in other phase I studies for
mobilization of stem cells for patients with myeloma and lymphoma. We have shown that the
combination of plerixafor and bortezomib is very effective in killing myeloma cells in the
laboratory more than the effect of each drug alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Genzyme, a Sanofi Company Millennium Pharmaceuticals, Inc.